Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash & Equivalents (2017 - 2025)

Protagonist Therapeutics' Cash & Equivalents history spans 9 years, with the latest figure at $128.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 32.02% year-over-year to $128.4 million; the TTM value through Dec 2025 reached $128.4 million, up 32.02%, while the annual FY2025 figure was $128.4 million, 32.02% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $128.4 million at Protagonist Therapeutics, up from $113.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $355.6 million in Q2 2024 and bottomed at $83.0 million in Q1 2021.
  • The 5-year median for Cash & Equivalents is $129.8 million (2024), against an average of $155.2 million.
  • The largest annual shift saw Cash & Equivalents soared 95.77% in 2023 before it plummeted 52.61% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $123.7 million in 2021, then rose by 1.68% to $125.7 million in 2022, then skyrocketed by 48.5% to $186.7 million in 2023, then crashed by 47.92% to $97.2 million in 2024, then soared by 32.02% to $128.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Cash & Equivalents are $128.4 million (Q4 2025), $113.7 million (Q3 2025), and $168.5 million (Q2 2025).